je.st
news
Regulus Therapeutics Inc (RGLS) Earns Buy Rating from Analysts at Chardan Capital
2016-04-14 08:07:13| Biotech - Topix.net
The brokerage set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. Chardan Capital's target price suggests a potential upside of 91.08% from the company's previous close.
Tags: buy
rating
capital
analysts
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||